Novo Nordisk (NVO) Price & Analysis

Compare

12,911 Followers

NVO Stock Chart & Stats

$49.16

$1.93(2.32%)

At close: Jan 08 4:00 PM EST

$49.16

$1.93(2.32%)

Day’s Range― - ―

52-Week Range$45.05 - $112.52

Previous CloseN/A

Volume3.65M

Average Volume (3M)15.63M

Market Cap

$214.89B

Enterprise Value$257.56B

Total Cash (Recent Filing)$32.58B

Total Debt (Recent Filing)$101.21B

Price to Earnings (P/E)14.0

Beta1.13

Next Earnings

Feb 04, 2026

EPS Estimate

0.93

Last Dividend Ex-Date

Aug 18, 2025

Dividend Yield3.83%

Share Statistics

EPS (TTM)0.69

Shares Outstanding3,390,128,000

10 Day Avg. Volume24,715,199

30 Day Avg. Volume15,625,699

Financial Highlights & Ratios

PEG Ratio1.28

Price to Book (P/B)19.23

Price to Sales (P/S)9.50

P/FCF Ratio39.62

Enterprise Value/Market Cap1.20

Enterprise Value/Revenue0.82

Enterprise Value/Gross Profit0.99

Enterprise Value/Ebitda1.57

Forecast

1Y Price Target

$60.39

Price Target Upside22.84% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Exclusive DealsCVS Caremark exclusive deal provides a tailwind for Wegovy despite ongoing issues.

Organizational RestructuringNovo management, under the leadership of new CEO Doustdar, announced a significant organizational restructuring aimed at delivering an estimated DKK 8B of savings by YE2026.

Regulatory ApprovalsFDA's publication of a GLP-1 API 'Green List' is a mild regulatory win for Novo.

Bears Say

Market CompetitionNovo Nordisk shares are expected to remain less competitive against peers in the cardiometabolic market.

Pricing And Patent ChallengesIRA pricing and patent expiration impacts are expected to be a drag on global sales.

Product CompetitionLilly's Mounjaro and Zepbound are expected to continue taking incremental U.S. share from Ozempic and Wegovy.

Novo Nordisk News

Tiger Global buys Netflix, exits Eli Lilly in Q3

Chase Coleman’s Tiger Global disclosed in an SEC filing its holdings as of September 30, 2025. Tiger’s new...

2d ago

Mixed options sentiment in Novo Nordisk with shares down 1.65%

Mixed options sentiment in Novo Nordisk (NVO), with shares down 81c near $48.35. Options volume running well above...

2d ago

NVO

Novo Nordisk price target lowered to DKK 400 from DKK 425 at Berenberg

Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 400 from DKK 425 and keeps...

2d ago

NVO

Novo Nordisk (NVO) Gets New Chair — Can It Catch Up with Rival Eli Lilly in Obesity Market?

Novo Nordisk’s ($NVO) shares fell modestly on Friday after its recent boardroom drama culminated in its top owner...

2d ago

LLY

NVO

Scholar Rock sees third-party facility ready for reinspection by end of year

Scholar Rock (SRRK) said Thursday that it had a Type A meeting with the U.S. FDA. The meeting...

2d ago

NVO

SRRK

Investors Flee Mangoceuticals Stock (MGRX) after Eli Lilly and Novo Nordisk Deny Partnership

Investors continued to dump shares of telehealth company Mangoceuticals ($MGRX) during early trading on Friday. This came after...

2d ago

LLY

NVO

Pfizer Stock (PFE) Rises as Metsera Shareholders Approve $10B Acquisition

Pfizer’s shares ($PFE) edged higher on Thursday after shareholders of Metsera ($MTSR) approved the American pharma giant’s offer...

3d ago

LLY

NVO

Investors plan protest vote against Novo Nordisk board shakeup, Reuters reports

Novo Nordisk (NVO) faces a shareholder backlash as minority investors plan a protest vote against a board overhaul...

3d ago

LLY

NVO

Novo denies partnership with Mangoceuticals on obesity drug, Reuters says

Novo Nordisk (NVO) and Eli Lilly (LLY) do not have a weight-loss drug partnership with telehealth website Mangoceuticals...

3d ago

LLY

NVO

Eli Lilly says ‘no affiliation’ with Mangoceuticals

Eli Lilly (LLY) said it “has no affiliation with Mangoceuticals. Any communication or media report suggesting a partnership...

3d ago

LLY

NVO

Hims & Hers Stock (HIMS) Plunges despite New ‘Affordable’ Healthcare Platform

Hims & Hers Health’s ($HIMS) shares continued to plunge on Thursday despite the consumer telehealth company launching a...

3d ago

LLY

NVO

Mangoceuticals Stock (MGRX) Soars on Deal to Sell Obesity Drugs for Eli Lilly, Novo Nordisk

Shares of Mangoceuticals ($MGRX), the Texas-based telehealth company focused on men’s health, rose sharply in early trading on Thursday,...

3d ago

AZN

LLY

Eli Lilly price target raised to $1,171 from $1,090 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Eli Lilly (LLY) to $1,171 from $1,090...

3d ago

LLY

NVO

Mangoceuticals partner with Eli Lilly, Novo, provide access to Zepbound, Wegovy

Mangoceuticals (MGRX) announces that it has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct...

3d ago

LLY

NVO

NVO FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest stock price was $45.05 and its highest was $112.52 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is $214.89B.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is Feb 04, 2026 which is in 80 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Nov 05, 2025. The company reported $0.692 earnings per share for the quarter, missing the consensus estimate of $0.764 by -$0.072.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novo Nordisk pay dividends?

Novo Nordisk pays a Semiannually dividend of $0.584 which represents an annual dividend yield of 3.83%. See more information on Novo Nordisk dividends here

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 0.93.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of $0.692 in its last earnings report, missing expectations of $0.764. Following the earnings report the stock price went up 0.435%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in NVO

Novo Nordisk Stock Smart Score

Neutral

Fundamentals

Return on Equity

68.30%

Trailing 12-Months

Asset Growth

35.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Novo Nordisk

Novo Nordisk is a global healthcare company based in Denmark, specializing in the development and manufacturing of pharmaceutical products. The company primarily focuses on diabetes care, obesity care, hemophilia care, and hormone replacement therapy. Novo Nordisk is a leader in diabetes treatments, offering a range of insulin products and GLP-1 receptor agonists, as well as therapies for other chronic conditions such as growth disorders and hemophilia.

Novo Nordisk (NVO) Earnings & Revenues

Historic Earnings Reports

NVO Company Deck

NVO Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted strong growth in sales and continued expansion in obesity care, supported by strategic acquisitions. However, significant challenges remain, including market share loss, restructuring efforts, and pricing pressures.View all NVO earnings summaries

NVO Stock 12 Month Forecast

Average Price Target

$60.39

▲(22.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","62":"$62","78":"$78","94":"$94","110":"$110"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$47.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,62,78,94,110],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.46,51.04,52.62,54.2,55.78,57.36,58.94,60.519999999999996,62.1,63.68,65.26,66.84,68.42,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.46,50.300769230769234,51.14153846153846,51.98230769230769,52.823076923076925,53.66384615384615,54.504615384615384,55.34538461538462,56.18615384615384,57.026923076923076,57.86769230769231,58.708461538461535,59.54923076923077,{"y":60.39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.46,49.27076923076923,49.081538461538464,48.892307692307696,48.70307692307692,48.51384615384615,48.324615384615385,48.135384615384616,47.94615384615385,47.75692307692308,47.567692307692305,47.378461538461536,47.18923076923077,{"y":47,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":109.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.87,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.26,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.27,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.17,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >